Trials / Completed
CompletedNCT03076268
TMP-Visitas al Hogar
Treinta Millones de Palabras-Visitas al Hogar Pilot Randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Treinta Millones de Palabras- Visitas al Hogar (TMP) is designed to intervene upon mothers' knowledge, beliefs, and behavior, which in turn influences their interaction with their children, impacting children's development. The investigators will measure change in mothers' knowledge, beliefs, and behavior during and after intervention, and measure impacts on children's development across major developmental domains. Specifically, the investigators will measure mothers' 1. Knowledge of child language development and the role of parents in that development 2. Beliefs about the malleability of intelligence and their role in shaping their children's intelligence 3. Interaction with their child, specifically their linguistic input and responsiveness to their child's communication Concurrently, the investigators will measure children's 1. Emergent oral language development, in both Spanish and English 2. Social-emotional development 3. Math and spatial reasoning skill development
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Treinta Millones de Palabras - Visitas al Hogar | TMP-Visitas al Hogar is a cultural and linguistic adaptation of the TMW-Home Visiting curriculum into Spanish. The 12-module curriculum has been translated into Spanish and adapted to address concerns that are vital to mono- and bilingual Spanish-speaking families, including the broadening research base for when to introduce a second language to a child and the benefits of bilingualism. |
Timeline
- Start date
- 2017-03-02
- Primary completion
- 2019-08-29
- Completion
- 2019-08-29
- First posted
- 2017-03-10
- Last updated
- 2023-05-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03076268. Inclusion in this directory is not an endorsement.